Abstract

Background: Temperature-sensitive radiopharmaceutical precursors require lower reaction temperatures (<100 °C) during nucleophilic radiofluorination in order to avoid compound thermolysis, often resulting in sub-optimal radiochemical yields (RCYs). To facilitate nucleophilic aromatic substitution (SNAr) of nucleofuges commonly used in radiofluorination (e.g., nitro group), we explored the use of Lewis acids as nucleophilic activators to accelerate [18F]fluoride incorporation at lower temperatures, and thereby increasing RCYs for thermolabile activated precursors. Lewis acid-assisted radiofluorination was exemplified on the temperature-sensitive compound 1-(4-(4-morpholino-7-neopentyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl)phenyl)-3-(6-nitropyridin-3-yl)urea (MN3PU, compound 3) targeting leucine-rich repeat kinase 2 (LRRK2), an important target in the study of Parkinson’s disease and various cancers. Methods: To a vessel containing dried K[18F]F-K222 complex, a solution of precursor MN3PU ((3), 1 mg; 1.8 μmol) and Lewis acid (6 μL of 0.2 μmol: chromium II chloride (A), ferric nitrite (B) or titanocene dichloride (C)) in 500 μL of N,N-dimethylformamide (DMF) (with 10% t-BuOH for B) were added. Reactions were stirred for 25 min at 90 °C. In parallel, reactions were conducted without the addition of Lewis acids for baseline comparison. After purification via preconditioned Sep-Pak C18 plus cartridges, aliquots were analyzed by analytical radio-HPLC. Results: Non-decay corrected radiochemical yields (ndc RCYs) for [18F]FMN3PU (7) were improved from 1.7 ± 0.7% (no addition of Lewis acids) to 41 ± 1% using Cr(II) and 37 ± 0.7% using Ti(II)-based Lewis acids, with radiochemical purities of ≥96% and molar activities (Am) of up to 3.23 ± 1.7 Ci/μmol (120 ± 1.7 GBq/μmol). Conclusion: RCYs of [18F]FMN3PU (7) improved from ~5% using conventional nucleophilic radiofluorination, up to 41 ± 1% using Lewis-acid supported SNAr.

Highlights

  • The production of [18 F]fluorinated radiopharmaceuticals for positron emission tomography (PET)imaging typically involves syntheses via nucleophilic substitution (SN ) [1]

  • Molecules 2020, 25, 4710 aryl-rings, including the deoxifluorination of phenols via Ru π-complexes [2], the substitution of aryl sulfonium salts [3], as well as iodonium, boronates or stannyl salts mediated by Cu, Ni or Pd catalysts including the deoxifluorination of phenols via Ru π-complexes [2], the substitution of aryl sulfonium

  • The products were formed after the reaction of (FMN3PU, 4) were performed as reported elsewhere [4]

Read more

Summary

Introduction

The production of [18 F]fluorinated radiopharmaceuticals for positron emission tomography (PET)imaging typically involves syntheses via nucleophilic substitution (SN ) [1]. Over the past few years, there has been tremendous development in radiofluorination chemistry involving both activated- and deactivated aryl-rings, Molecules 2020, 25, 4710; doi:10.3390/molecules25204710 www.mdpi.com/journal/molecules. Molecules 2020, 25, x FOR PEER REVIEW tremendous development in radiofluorination chemistry involving both activated- and deactivated. Pd catalysts compounds containing a pyridine ring, the. Temperature-sensitive radiopharmaceutical precursors require lower reaction temperatures (

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call